Navigation Links
Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Date:9/24/2010

tary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.  Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Unigene's technologies have extensive clinical and partner validation.  The Company's first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis.  Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, now in Phase 3 testing for the treatment of osteoporosis.  Other validating relationships include an oral parathyroid hormone nearing Phase 2 and licensed to GlaxoSmithKline.  In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.

For more information about Unigene, please visit http://www.unigene.com.  For information about Fortical, please visit http://www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including with respect to clinical studies of one of our licensees. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
2. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
3. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
4. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
8. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
9. Trius Therapeutics Reports 2010 Second Quarter Results
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... and OSAKA, Japan ... Cell Research Application (CiRA) of Kyoto University and ... they will work together to develop clinical applications ... as heart failure, diabetes mellitus, neurological disorders and ... Cell Applications" (T-CiRA) is designed to expedite multiple ...
(Date:4/16/2015)... Irvine, CA (PRWEB) April 16, 2015 ... in the Buzz of BIO Contest for ... Industry Organization (BIO), the 2015 BIO International Convention will ... in Philadelphia, Pennsylvania. During the Buzz of BIO contest, ... like to see present at the conference. The community ...
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... Research Group plc (AIM:,PRG) announces the appointment of ... Resources. Mr. Keenen will be responsible for setting ... the,effectiveness of Premier Research,s people and organization in ... McCall, COO, commented: "We are very pleased to ...
... biometrics access control ... approved products list for airports, TORONTO, Sept. 18 /PRNewswire-FirstCall/ ... control technology, today announced,that its V-Station MIFARE V9.50 has been ... TSA,s "Biometrics for,Access Control" Qualified Products List (QPL). Products ...
... BOSTON, Sept. 18 PAREXEL Consulting, a,business unit ... a leading global,life sciences consultancy serving the bio/pharmaceutical ... strengthening its Good Manufacturing,Practice (GMP) capabilities in Europe ... European Union (EU) directives in areas such as,manufacturing ...
Cached Biology Technology:Premier Research Appoints Global Head of Human Resources 2Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 2Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 3Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 2Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 3Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 4Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 5Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 6
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... -- Reseachers at The Ohio State University have ... an effective method for preserving the important genetic diversity ... geranium, are some of the most popular flowers the ... Society listed more than 3,000 varieties of geranium in ...
... -- Two common dietary molecules found in legumes ... effects of radiation, researchers from the University of ... both human skin cells and a skin cancer-prone ... the damaging radiation found in sunlight, the team ...
... scientists today announced the results of a systematic effort ... worlds leading cause of cancer deaths. Appearing in the ... the research provides a comprehensive view of the abnormal ... 50 genomic regions that are frequently gained or lost ...
Cached Biology News:'TRAP' preserves genetic properties of popular geranium 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3Genome study charts genetic landscape of lung cancer 2Genome study charts genetic landscape of lung cancer 3
...
... Gene expression profiling allows a high-throuput ... that naturally occuring or artifitially induced changes ... in that system can be detected, studied, ... a broad range of genes at a ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
RORgamma (S-14)...
Biology Products: